HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

Abstract Background Triple negative breast cancer (TNBC) represents a significant clinical challenge. Chemotherapy remains the mainstay for a large part of TNBC patients, whereas drug resistance and tumor recurrence frequently occur. It is in urgent need to identify novel molecular targets for TNBC...

Full description

Bibliographic Details
Main Authors: Hui Lyu, Fei Shen, Sanbao Ruan, Congcong Tan, Jundong Zhou, Ann D. Thor, Bolin Liu
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Cancer Cell International
Subjects:
HER3
EGFR
Blocking antibody
Targeted therapy
Paclitaxel
TNBC
Online Access:https://doi.org/10.1186/s12935-023-03055-w

Internet

https://doi.org/10.1186/s12935-023-03055-w

Similar Items